Tumor microenvironment-response calcium phosphate hybrid nanoparticles enhanced siRNAs targeting tumors in vivo

Zhihua Wu; Jianhua Chen; Ying Sun; De Zhao; Ming Shen; Lili Huang; Qing Xu; Yourong Duan; Yaogang Li

doi:10.1166/jbn.2018.2606

Tumor microenvironment-response calcium phosphate hybrid nanoparticles enhanced siRNAs targeting tumors in vivo

Zhihua Wu, Jianhua Chen, Ying Sun, De Zhao, Ming Shen, Lili Huang, Qing Xu, Yourong Duan, Yaogang Li^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Short interfering RNA (siRNA)-based therapy has a high potential for application in cancer gene therapy. However, delivery of siRNA to target cells is limited by many factors such as serum ribonuclease (RNase) degradation, off-target effects, and inadequate cellular uptake. In this study, an enzyme-response PEG/Lipids/calcium phosphate hybrid delivery system was constructed for siRNA. The nearly neutral charged siRNA@NP2 was resistant to serum-induced degradation. Compared with the non-enzyme-response siRNA@NP1, siRNA@NP2 had efficient delivery in both SMMC-7721 cell lines and SMMC-7721-bearing nude mice. Moreover, safety evaluation of the nanoparticles revealed that they had no significant toxicity both in vitro and in vivo. The developed siRNA@NP2 delivery system presents an efficient tool for siRNA-based cancer gene therapy in vivo.

Original language	English
Pages (from-to)	1816-1825
Number of pages	10
Journal	Journal of Biomedical Nanotechnology
Volume	14
Issue number	10
DOIs	https://doi.org/10.1166/jbn.2018.2606
Publication status	Published - Oct 2018
Externally published	Yes

Keywords

Cancer Gene Therapy
Delivery System
Matrix Metalloproteinase
SiRNA Delivery
Targeting

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1166/jbn.2018.2606

Cite this

@article{e08aa97f3a28467eab6f4780e4fec692,

title = "Tumor microenvironment-response calcium phosphate hybrid nanoparticles enhanced siRNAs targeting tumors in vivo",

abstract = "Short interfering RNA (siRNA)-based therapy has a high potential for application in cancer gene therapy. However, delivery of siRNA to target cells is limited by many factors such as serum ribonuclease (RNase) degradation, off-target effects, and inadequate cellular uptake. In this study, an enzyme-response PEG/Lipids/calcium phosphate hybrid delivery system was constructed for siRNA. The nearly neutral charged siRNA@NP2 was resistant to serum-induced degradation. Compared with the non-enzyme-response siRNA@NP1, siRNA@NP2 had efficient delivery in both SMMC-7721 cell lines and SMMC-7721-bearing nude mice. Moreover, safety evaluation of the nanoparticles revealed that they had no significant toxicity both in vitro and in vivo. The developed siRNA@NP2 delivery system presents an efficient tool for siRNA-based cancer gene therapy in vivo.",

keywords = "Cancer Gene Therapy, Delivery System, Matrix Metalloproteinase, SiRNA Delivery, Targeting",

author = "Zhihua Wu and Jianhua Chen and Ying Sun and De Zhao and Ming Shen and Lili Huang and Qing Xu and Yourong Duan and Yaogang Li",

year = "2018",

month = oct,

doi = "10.1166/jbn.2018.2606",

language = "English",

volume = "14",

pages = "1816--1825",

journal = "Journal of Biomedical Nanotechnology",

issn = "1550-7033",

publisher = "American Scientific Publishers",

number = "10",

}

TY - JOUR

T1 - Tumor microenvironment-response calcium phosphate hybrid nanoparticles enhanced siRNAs targeting tumors in vivo

AU - Wu, Zhihua

AU - Chen, Jianhua

AU - Sun, Ying

AU - Zhao, De

AU - Shen, Ming

AU - Huang, Lili

AU - Xu, Qing

AU - Duan, Yourong

AU - Li, Yaogang

PY - 2018/10

Y1 - 2018/10

N2 - Short interfering RNA (siRNA)-based therapy has a high potential for application in cancer gene therapy. However, delivery of siRNA to target cells is limited by many factors such as serum ribonuclease (RNase) degradation, off-target effects, and inadequate cellular uptake. In this study, an enzyme-response PEG/Lipids/calcium phosphate hybrid delivery system was constructed for siRNA. The nearly neutral charged siRNA@NP2 was resistant to serum-induced degradation. Compared with the non-enzyme-response siRNA@NP1, siRNA@NP2 had efficient delivery in both SMMC-7721 cell lines and SMMC-7721-bearing nude mice. Moreover, safety evaluation of the nanoparticles revealed that they had no significant toxicity both in vitro and in vivo. The developed siRNA@NP2 delivery system presents an efficient tool for siRNA-based cancer gene therapy in vivo.

AB - Short interfering RNA (siRNA)-based therapy has a high potential for application in cancer gene therapy. However, delivery of siRNA to target cells is limited by many factors such as serum ribonuclease (RNase) degradation, off-target effects, and inadequate cellular uptake. In this study, an enzyme-response PEG/Lipids/calcium phosphate hybrid delivery system was constructed for siRNA. The nearly neutral charged siRNA@NP2 was resistant to serum-induced degradation. Compared with the non-enzyme-response siRNA@NP1, siRNA@NP2 had efficient delivery in both SMMC-7721 cell lines and SMMC-7721-bearing nude mice. Moreover, safety evaluation of the nanoparticles revealed that they had no significant toxicity both in vitro and in vivo. The developed siRNA@NP2 delivery system presents an efficient tool for siRNA-based cancer gene therapy in vivo.

KW - Cancer Gene Therapy

KW - Delivery System

KW - Matrix Metalloproteinase

KW - SiRNA Delivery

KW - Targeting

UR - https://www.scopus.com/pages/publications/85054234936

U2 - 10.1166/jbn.2018.2606

DO - 10.1166/jbn.2018.2606

M3 - Article

C2 - 30041727

AN - SCOPUS:85054234936

SN - 1550-7033

VL - 14

SP - 1816

EP - 1825

JO - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

IS - 10

ER -

Tumor microenvironment-response calcium phosphate hybrid nanoparticles enhanced siRNAs targeting tumors in vivo

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this